Chembond Materi. (CHEMBOND)

Score breakdown: P/E: 2/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Trades at P/B of 0.76, below book value of ₹187.43.
• Very low Debt/Equity of 0.04 provides strong balance sheet protection.
• Promoter holding of 67.72% aligns management interests with minority shareholders.
• Sales growth of 18.57% shows the business is expanding despite margin pressure.
• ROCE of 11.54% is reasonable relative to the minimal debt level.

Concerns

• Net profit declined 24.38% even as sales grew, with latest quarter margin of only ~3.2%.
• ROE of 3.56% signals poor returns on shareholder equity.
• Piotroski F-Score of 4/9 indicates deteriorating fundamentals.
• Low P/E of 14.50 could be a value trap if earnings continue to fall.

AI Analysis

Let's look at Chembond Materi. I don't buy businesses just because the numbers look cheap; I buy good businesses when the price makes sense. Here, a specialty chemicals firm sits at ₹143.25 against book value of ₹187.43—about 0.76 times book. The market capitalisation is ₹198 crore, so you're paying a significant discount to net assets. That is the Graham side: a margin of safety on the balance sheet. But the Buffett side asks: is it a wonderful business? The evidence is mixed. Sales grew 18.57%, but profits fell 24.38%. The latest quarter earned only ₹2 crore on ₹63 crore of sales, a thin profit margin. ROE is just 3.56%, far below what I expect from a quality compounder. ROCE is 11.54%, which is acceptable, but not exceptional. Debt-to-equity is 0.04, so the company is not leveraged; that protects the downside. Promoter holding at 67.72% is reassuring; they own the business alongside me. P/E of 14.50 is not demanding, but with earnings declining, a low P/E can be deceptive. Piotroski score of 4/9 suggests deteriorating fundamentals, not a healthy improving business. Dividend yield 1.19% is modest. So what is this? It looks like an asset play: a low-debt specialty chemicals company trading below book with depressed profitability. I need a catalyst: better margins, higher ROE, or capital discipline. If it can translate sales growth into profit, the leverage is very low and the book value provides support. If not, the cheapness may be a value trap. I'd watch closely, not rush in. In Ben Graham's words, buy with a margin of safety; but also remember that a mediocre business can remain mediocre.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer